Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
The cancer immunotherapy market is projected to grow significantly, primarily due to the rising prevalence of cancer and increased exposure to carcinogens. DelveInsight's report indicates North America will maintain its dominance in the market, expected to reach USD 162.87 billion by 2027, with a CAGR of ~12% from 2022-2027. Key players include Amgen, AstraZeneca, and Merck, among others. Recent advancements include FDA fast-track designation for Evaxion Biotech's EVX-01 in combination with KEYTRUDA. However, challenges such as high treatment costs and adverse effects remain. The full report provides insights on market dynamics and key drivers.
Evaxion Biotech (NASDAQ: EVAX) and Pantherna Therapeutics announced successful preclinical proof of concept for combining their technologies, showing that tumor neoantigens identified by Evaxion's AI platform can inhibit tumor growth when delivered via Pantherna's lipid nanoparticle mRNA platform. This collaboration aims to enhance mRNA delivery and effectiveness in immuno-oncology and infectious diseases. Both companies express optimism about the potential of their combined technologies, with further exploration of optimal formulations for mRNA and DNA-encoded antigens expected.
Evaxion Biotech A/S (NASDAQ: EVAX) announced that the FDA granted fast track designation for its personalized cancer therapy EVX-01, in combination with KEYTRUDA®. This designation is aimed at expediting the approval process for innovative drugs addressing unmet medical needs. Evaxion's CEO, Per Norlén, emphasized the potential patient benefits and the validation of their AI platform, PIONEER. The ongoing Phase 2b trial is conducted in the U.S., Europe, and Australia, initiated in September 2022, with the first patient enrolled in Australia. This trial is a collaboration with Merck, utilizing the PD-1 inhibitor KEYTRUDA®.
Evaxion Biotech A/S (NASDAQ: EVAX) has received FDA approval to proceed with its Phase 2b clinical trial of EVX-01 for treating metastatic melanoma. The trial will investigate the efficacy of EVX-01 in combination with KEYTRUDA and is currently enrolling patients in Australia, with plans to expand to the U.S. and Europe. The FDA's endorsement is a significant milestone for Evaxion’s personalized cancer vaccine initiative, enhancing its capability to demonstrate clinical benefits. A response regarding the Fast Track designation is expected in Q1 2023.
Evaxion Biotech A/S (NASDAQ: EVAX) announced plans to present data from its clinical trials on personalized cancer immunotherapies EVX-01 and EVX-02 in Q2 2023. The trials focus on metastatic melanoma and resected malignant melanoma. Promising interim results were reported, showing high response rates for EVX-01 and robust T-cell responses for EVX-02. EVX-01 is currently in Phase 2b, in combination with Merck's Keytruda. CEO Per Norlén expressed excitement about the advancements in their AI-driven immunotherapy programs, positioned to lead in next-generation cancer treatments.
Evaxion Biotech (NASDAQ: EVAX) has entered into a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB. This partnership aims to develop a novel cytomegalovirus (CMV) vaccine candidate utilizing Evaxion's AI platform, RAVEN, for antigen design. Costs for the collaboration will be split evenly until 2025. A potential future agreement could provide Evaxion with milestone payments and royalties based on CMV asset sublicensing. CMV represents a significant unmet medical need, especially for immunocompromised individuals and congenitally infected infants.
Evaxion Biotech A/S (NASDAQ: EVAX) announced promising interim data from its Phase 1/2a clinical trial for its DNA-based cancer immunotherapy, EVX-02. The treatment, aimed at melanoma, showed a well-tolerated safety profile with only mild adverse events. All patients exhibited robust CD4+ and CD8+ T-cell responses, highlighting the efficacy of their AI-driven technology for personalized cancer treatment. A full report of the trial results is expected in Q2 2023, as the company looks forward to advancing their next-generation DNA technology.
Evaxion Biotech (NASDAQ: EVAX) announced its Q3 2022 financial results, highlighting the enrollment of the first patient in a Phase 2b trial for its cancer immunotherapy EVX-01. The company reported cash and equivalents of $17.9 million, sufficient to support operations into mid-2023. The R&D expenses decreased to $4.1 million compared to $4.4 million in Q3 2021, while general and administrative expenses rose to $2.0 million. Despite a net loss of $5.7 million for the quarter, Evaxion is focused on its oncology assets and pursuing strategic partnerships. Guidance remains optimistic for ongoing projects.
Evaxion Biotech (NASDAQ: EVAX) announced a strategic shift to focus on its leading oncology assets, EVX-01 and EVX-02/03, aiming for clinical proof of concept before potential out-licensing. New CEO Per Norlén emphasized the need for concentration on personalized cancer immunotherapies while preclinical infectious disease programs will seek partnerships. The Phase IIb trial for EVX-01 is underway, with mid-2023 data expected for EVX-02. Promising pre-clinical results for EVX-03 suggest superior efficacy, with plans for regulatory submission following EVX-02 outcomes.
Abalos Therapeutics has appointed Thomas Bogenrieder, MD, PhD, as its new Chief Medical Officer. Dr. Bogenrieder brings over 17 years of international experience in clinical development, particularly in cancer immunotherapies. His expertise will bolster Abalos' efforts in clinical and regulatory strategies for its arenavirus-based product candidates aimed at treating solid tumors. Previously, he served as Chief Medical Officer at Evaxion Biotech and has held senior roles at Boehringer Ingelheim and GlaxoSmithKline. This leadership change is expected to enhance Abalos' innovation in cancer treatment.